DEXILANT dosing recommendations for adult patients1

Adult dosing table

DEXILANT 30 mg should be considered for patients with moderate hepatic impairment.

DEXILANT use is not recommended in patients with severe hepatic impairment.

*Controlled studies did not extend beyond 6 months.

DEXILANT is approved for patients age 12–17 years

Recommended dosage regimen by indication for patients age 12–17 years

Patients 12-17 years of age dosing table

DEXILANT 30 mg should be considered for patients with moderate hepatic impairment.

DEXILANT use is not recommended in patients with severe hepatic impairment.

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well-controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.

Controlled studies did not extend beyond 16 weeks.

DEXILANT capsules can be taken with or without food1

Unlike lansoprazole, esomeprazole, and omeprazole, which should be taken before eating, DEXILANT can be taken without regard to food.

  • DEXILANT capsules should be swallowed whole; do not chew
  • Alternatively, capsules can be opened, sprinkled on 1 tablespoon of applesauce, and swallowed immediately. Granules should not be chewed. Do not store for later use
  • Alternatively, the capsule can be opened for administration with water via oral syringe or nasogastric tube. Please see the full prescribing information for additional administration instructions.

98%3 of adult patients said that DEXILANT was convenient to take and that the dosing fit their daily schedule.

Based on an internet survey conducted January 2011 of 4013 adult users who were self-reported, physician-diagnosed, with GERD/Acid Reflux Disease/EE.

HELP YOUR PATIENTS SAVE ON DEXILANT

With the DEXILANT Instant Savings Card, most commercially insured patients pay no more than $20§ for their DEXILANT capsule prescriptions and refills.

LEARN ABOUT SAVINGS

§Must meet Eligibility Requirements. This savings card covers out-of-pocket expenses greater than $20, up to a maximum benefit of $55 for a 30-day prescription or $165 for a commercially insured 90-day prescription. Most commercially insured patients pay no more than $20 for a 90-day prescription for appropriate patients.

Savings card cannot be used with government programs such as Medicare Part D and Medicaid.

  1. DEXILANT (dexlansoprazole) prescribing information. Takeda Pharmaceuticals.
  2. Metz DC, Howden CW, Perez MC, et al. Aliment Pharmacol Ther. 2009;29:742‐754.
  3. Data on file. Takeda Pharmaceuticals.
  4. Vakily M, Zhang W, Wu J, et al. Curr Med Res Opin. 2009;25:627-638.

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • PPIs, including DEXILANT, are contraindicated with rilpivirine‑containing products.
  • In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow‑up and diagnostic testing.
  • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Long‑term (≥ 1 year) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis‑related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated.
  • New onset or worsening of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. The majority of PPI‑induced lupus erythematosus cases were CLE. Avoid administration of PPIs for longer than medically indicated. Discontinue DEXILANT and refer the patient to an appropriate specialist for evaluation, if signs or symptoms of CLE or SLE occur. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks.
  • Daily treatment with any acid‑suppressing medications over a long period of time (e.g., > 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (Vitamin B‑12).
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Serum chromogranin A (CgA) levels increase secondary to drug‑induced decreases in gastric acidity which may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop DEXILANT treatment ≥ 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of DEXILANT.
  • Most commonly reported adverse reactions in adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • The adverse reaction profile in patients age 12 to 17 years was similar to adults. The most commonly reported adverse reactions in patients age 12 to 17 years (≥ 5%) were headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
  • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with DEXILANT may reduce antiviral effect. Avoid concomitant use of nelfinavir with DEXILANT. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with DEXILANT may increase toxicity of the antiretroviral drugs.
  • Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time (PT). Increases in INR and PT time may lead to abnormal bleeding and even death.
  • DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., digoxin, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil [MMF], ketoconazole/itraconazole). Use DEXILANT with caution in transplant patients receiving MMF.
  • Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
  • A hyper‑response in gastrin secretion in response to the secretin stimulation test may falsely suggest gastrinoma. Temporarily stop DEXILANT treatment ≥ 30 days before assessing to allow gastrin levels to return to baseline.
  • Avoid concomitant use of DEXILANT with St. John’s Wort or rifampin due to decreased exposure of DEXILANT.
  • No studies have been conducted in patients with severe hepatic impairment (Child‑Pugh Class C). The use of DEXILANT is not recommended for these patients.

Indications

DEXILANT (dexlansoprazole) 30 mg and 60 mg delayed‑release capsules are indicated in patients ≥ age 12 years for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months in adults and up to 16 weeks in patients age 12 to 17 years
  • Treating heartburn associated with symptomatic non‑erosive gastroesophageal reflux disease (GERD) for 4 weeks

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well‑controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.


Please see full Prescribing Information, including Medication Guide for DEXILANT.

Important Safety Information

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • PPIs, including DEXILANT, are contraindicated with rilpivirine‑containing products.
  • In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow‑up and diagnostic testing.
  • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Long‑term (≥ 1 year) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis‑related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated.
  • New onset or worsening of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. The majority of PPI‑induced lupus erythematosus cases were CLE. Avoid administration of PPIs for longer than medically indicated. Discontinue DEXILANT and refer the patient to an appropriate specialist for evaluation, if signs or symptoms of CLE or SLE occur. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks.
  • Daily treatment with any acid‑suppressing medications over a long period of time (e.g., > 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (Vitamin B‑12).
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Serum chromogranin A (CgA) levels increase secondary to drug‑induced decreases in gastric acidity which may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop DEXILANT treatment ≥ 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of DEXILANT.
  • Most commonly reported adverse reactions in adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • The adverse reaction profile in patients age 12 to 17 years was similar to adults. The most commonly reported adverse reactions in patients age 12 to 17 years (≥ 5%) were headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
  • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with DEXILANT may reduce antiviral effect. Avoid concomitant use of nelfinavir with DEXILANT. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with DEXILANT may increase toxicity of the antiretroviral drugs.
  • Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time (PT). Increases in INR and PT time may lead to abnormal bleeding and even death.
  • DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., digoxin, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil [MMF], ketoconazole/itraconazole). Use DEXILANT with caution in transplant patients receiving MMF.
  • Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
  • A hyper‑response in gastrin secretion in response to the secretin stimulation test may falsely suggest gastrinoma. Temporarily stop DEXILANT treatment ≥ 30 days before assessing to allow gastrin levels to return to baseline.
  • Avoid concomitant use of DEXILANT with St. John’s Wort or rifampin due to decreased exposure of DEXILANT.
  • No studies have been conducted in patients with severe hepatic impairment (Child‑Pugh Class C). The use of DEXILANT is not recommended for these patients.

Indications

DEXILANT (dexlansoprazole) 30 mg and 60 mg delayed‑release capsules are indicated in patients ≥ age 12 years for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months in adults and up to 16 weeks in patients age 12 to 17 years
  • Treating heartburn associated with symptomatic non‑erosive gastroesophageal reflux disease (GERD) for 4 weeks

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well‑controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.


Please see full Prescribing Information, including Medication Guide for DEXILANT.